Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

Positioning bsUST as a first line of treatment appears to be cost effective and an efficient alternative from the NHS perspective in Spain. Additionally, none of the alternative sequences proved to be cost effective compared with the sequence starting with bsADA-bsUST. bsUST may significantly impact Crohn's disease management in Spain, improving patient access due to its lower drug acquisition costs.